Hepatitis E – overview of the latest knowledge
Authors:
M. Mihalčin 1,2; P. Polák 1,2; P. Husa 1,2
Authors‘ workplace:
Lékařská fakulta Masarykovy Univerzity, Brno
1; Klinika infekčních chorob, Fakultní nemocnice Brno, přednosta prof. MUDr. Petr Husa, CSc.
2
Published in:
Epidemiol. Mikrobiol. Imunol. 64, 2015, č. 2, s. 72-78
Category:
Review Article
Overview
Hepatitis E (HE) is a ubiquitous infection, occurring both in developing and in developed countries. It is caused by the hepatitis E virus (HEV), a small, non-enveloped RNA virus. The reported incidence in the Czech Republic in 2013 was 2 cases per 100 000 inhabitants and the number of HE cases has been growing over the past years. Besides the long known fecal-oral transmission, zoonotic and blood product transmission of HEV has recently been observed in industrialized countries. Most infections are asymptomatic. Symptomatic infection may present as acute hepatitis with nonspecific flu-like symptoms and liver enzymes elevation. In immunocompromised patients, HEV can lead to chronic hepatitis E and can even cause acute liver failure in pregnant women. Several extrahepatic manifestations have also been reported. Antiviral therapy has been successfully used in chronic hepatitis E. The first vaccine available for clinical use is licensed in China so far.
Keywords:
hepatitis E – HEV – review – Czech Republic
Sources
1. Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology, 1983;20:23–31.
2. Tsarev SA, Emerson SU, Reyes GR, et al. Characterization of a prototype strain of hepatitis E virus. Proc Natl Acad Sci USA, 1992;89:559–563.
3. Meng X-J, Purcell RH, Halbur PG, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci, 1997;94:9860–9865.
4. Ruggeri FM, Di Bartolo I, Ponterio E, et al. Zoonotic transmis-sion of hepatitis E virus in industrialized countries. New Microbiol, 2013;36:331–344.
5. Cao D, Meng X-J. Molecular biology and replication of hepatitis E virus. Emerg Microbes Infect 2012;1.
6. Ahmad I, Holla RP, Jameel S. Molecular virology of hepatitis E virus. Virus Res, 2011;161:47–58.
7. Mirazo S, Ramos N, Mainardi V et al. Transmission, diagnosis, and management of hepatitis E: an update. Hepatic Med Evid Res, 2014;6:45–59.
8. Haffar S, Bazerbachi F, Lake JR. Making the case for the develop-ment of a vaccination against hepatitis E virus. Liver Int Off J Int Assoc Study Liver, 2014.
9. Kannan H, Fan S, Patel D, et al. The Hepatitis E Virus Open Reading Frame 3 Product Interacts with Microtubules and Interferes with Their Dynamics. J Virol, 2009;83:6375–6382.
10. Pérez-Gracia MT, Suay B, Mateos-Lindemann ML. Review: Hepatitis E: An emerging disease. Infect Genet Evol, 2014;22:40–59.
11. Panda SK, Varma SPK. Hepatitis E: Molecular Virology and Pathogenesis. J Clin Exp Hepatol, 2013;3:114–124.
12. Rein DB, Stevens GA, Theaker J, et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatol Baltim Md, 2012;55:988–997.
13. Arends JE, Ghisetti V, Irving W, et al. Review: Hepatitis E: An emerging infection in high income countries. J Clin Virol, 2014;59:81–88.
14. Barnaud E, Rogée S, Garry P, et al. Thermal Inactivation of Infectious Hepatitis E Virus in Experimentally Contaminated Food. Appl Environ Microbiol, 2012;78:5153–5159.
15. Khuroo MS, Kamili S, Khuroo MS. Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. J Viral Hepat, 2009;16:519–523.
16. Coilly A, Haïm-Boukobza S, Roche B, et al. Posttransplantation hepatitis E: transfusion-transmitted hepatitis rising from the ashes. Transplantation, 2013;96:e4–6.
17. Schlosser B, Stein A, Neuhaus R, et al. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol, 2012;56:500–502.
18. Aggarwal R, Kamili S, Spelbring J, et al. Experimental studies on subclinical hepatitis E virus infection in cynomolgus macaques. J Infect Dis, 2001;184:1380–1385.
19. Aggarwal RA. Hepatitis E: Clinical presentation in disease-endemic areas and diagnosis. Semin Liver Dis, 2013;33:30–40.
20. Kim J-H, Nelson KE, Panzner U, et al. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infect Dis, 2014;14.
21. Shinde N, Patil T, Deshpande A, et al. Clinical Profile, Maternal and Fetal Outcomes of Acute Hepatitis E in Pregnancy. Ann Med Health Sci Res, 2014;4:S133–S139.
22. Navaneethan U, Al Mohajer M, Shata MT. Hepatitis E and pregnancy: understanding the pathogenesis. Liver Int, 2008;28:1190–1199.
23. Pal R, Aggarwal R, Naik SR, et al. Immunological alterations in pregnant women with acute hepatitis E. J Gastroenterol Hepatol, 2005;20:1094–1101.
24. Dalton HR, Bendall RP, Rashid M, et al. Host risk factors and autochthonous hepatitis E infection. J Gastroenterol, 2011;23:1200–1205.
25. Thapa R, Biswas B, Mallick D, et al. Acute pancreatitis - Complicating hepatitis E virus infection in a 7-year-old boy with glucose 6 phosphate dehydrogenase deficiency. Clin Pediatr (Phila), 2009;48:199–201.
26. Chalupa P, Holub M. Jaundice complicated by an atypical form of Guillain-Barré syndrome. J Clin Virol Off Publ Pan Am Soc Clin Virol, 2010;49:229–230.
27. Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatol Baltim Md, 2012;55:695–708.
28. Fujiwara S, Yokokawa Y, Morino K, et al. Chronic hepatitis E: A review of the literature. J Viral Hepat, 2014;21:78–89.
29. Kamar N, Garrouste C, Haagsma EB, et al. Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. Gastroenterology, 2011;140:1481–1489.
30. Grewal P, Kamili S, Motamed D. Chronic hepatitis E in an immunocompetent patient: A case report. Hepatology, 2014;59:347–348.
31. González Tallón AI, Moreira Vicente V, Mateos Lindemann ML et al. Hepatitis crónica E en paciente inmunocompetente. Gastroenterol Hepatol, 2011;34:398–400.
32. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and Treatment of Hepatitis E Virus Infection. Gastroenterology, 2012;142:1388–1397.e1.
33. Huang S, Zhang X, Jiang H, et al. Profile of Acute Infectious Markers in Sporadic Hepatitis E. PLoS ONE, 2010;5:e13560.
34. Aggarwal R, Jameel S. Hepatitis E. Hepatology, 2011;54:2218–2226.
35. Aggarwal R, Kini D, Sofat S et al. Duration of viraemia and faecal viral excretion in acute hepatitis E. The Lancet, 2000;356:1081–1082.
36. Alric L, Bonnet D, Laurent G, et al. Chronic hepatitis E virus infection: Successful virologic response to pegylated interferon-α therapy. Ann Intern Med, 2010;153:135–136.
37. Debing Y, Emerson SU, Wang Y, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother, 2014;58:267–273.
38. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. Gastroenterology, 2010;139:1612–1618.
39. Haagsma EB, Riezebos-Brilman A, van den Berg AP, et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc, 2010;16:474–477.
40. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: A single-centre experience. Liver Int, 2013;33:722–726.
41. Gerolami R, Borentain P, Raissouni F, et al. Treatment of severe acute hepatitis E by ribavirin. J Clin Virol Off Publ Pan Am Soc Clin Virol, 2011;52:60–62.
42. Giordani MT, Fabris P, Brunetti E, et al. Hepatitis E and lymphocytic leukemia in man, Italy. Emerg Infect Dis, 2013;19:2054–2056.
43. Neukam K, Barreiro P, Macías J, et al. Chronic hepatitis e in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis, 2013;57:465–468.
44. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med, 2012;367:1237–1244.
45. Debing Y, Neyts J. Antiviral strategies for hepatitis e virus. Antiviral Res, 2014;102:106–118.
46. Féray C, Pawlotsky J-M, Roque-Afonso A-M, et al. Should we screen blood products for hepatitis E virus RNA? The Lancet, 2014;383:218.
47. Shrestha MP, Scott RM, Joshi DM, et al. Safety and Efficacy of a Recombinant Hepatitis E Vaccine. N Engl J Med, 2007;356: 895–903.
48. Zhu F-C, Zhang J, Zhang X-F, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. The Lancet, 2010;376:895–902.
49. Park SB. Hepatitis E vaccine debuts. Nature, 2012;491:21–22.
50. Vybrané infekční nemoci v ČR v letech 2004–2013 – absolutně, SZÚ. http://www.szu.cz/publikace/data/vybrane-infekcni-nemoci-v-cr-v-letech-2003-2012-absolutne.
51. Trmal J, Beneš C, Trnková M. Odlišnosti výskytu virových hepatitid A a E v České republice. Epidemiol Mikrobiol Imunol , 2013;62:19–25.
52. Chalupa P, Vasickova P, Pavlik I, et al. Endemic Hepatitis E in the Czech Republic. Clin Infect Dis, 2014;58:509–516.
53. Trmal J, Pavlík I, Vašíčková P, et al. Epidemie virové hepatitidy E v České republice? Epidemiol Mikrobiol Imunol, 2012;61:15–20.
54. Berto A, Backer JA, Mesquita JR, et al. Prevalence and transmission of hepatitis e virus in domestic swine populations in different European countries. BMC Res Notes, 2012;5.
55. Vasickova P, Slany M, Chalupa P, et al. Detection and phylogenetic characterization of human hepatitis e virus strains, Czech Republic. Emerg Infect Dis, 2011;17:917–919.
56. Centers for Disease Control and Prevention. Epidemiology and Prevention of Viral Hepatitis A to E: An Overview. 2000. http://www.cdc.gov/hepatitis/HEV/HEVfaq.htm#a3.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2015 Issue 2
Most read in this issue
- The possibilities of zoonotic transmission of rotaviruses
- Toxoplasmosis in immunocompromised patients
- Hepatitis E – overview of the latest knowledge
- The prevalence of nasal carriage of Staphylococcus aureus aureus and methicillin-resistant S. aureus (MRSA) among general medicine students of the Palacky University Olomouc